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Abstract 
Objectives: This retrospective study aims to evaluate off-label prescriptions and 
administrations of psychotropic medications in adolescents in a university psychiatric hospital 
in Switzerland. 
Methods: Data were collected during the entire stays from the electronic database for 76 
inpatients in 2008 and 76 inpatients in 2014. Data collected included gender, age, psychiatric 
diagnosis, duration of hospitalization, psychotropic drug prescriptions and administrations. 
Results: A total of 224 psychotropic drugs (mean 2.9 drugs/patient) were prescribed in 2008 
and 268 (mean 3.5 drugs/patient) in 2014. Due to the prescriptions of some drugs as required, 
only 76% of the prescriptions were actually administered in 2008 (mean 2.3 drugs/patient) and 
55% in 2014 (mean 1.9 drugs/patient). Antipsychotics were the most frequently prescribed 
drugs in 2008 (74% of patients) and 2014 (86% of patients). Anxiolytics were also highly 
prescribed in 2008 (54% of patients) and 2014 (66% of patients), as well as antidepressants 
in 2008 (30% of patients), but less in 2014 (13% of patients). Overall, 69% of prescriptions 
were found to be off-label in 2008 and 68% in 2014, according to age, diagnosis, dose or 
formulation as approved by Swissmedic. The medication classes with the highest rate of off-
label prescriptions were antidepressants (100% for both years), antipsychotics (94% in 2008, 
92% in 2014) and hypnotics (67% in 2008, 100% in 2014). For both study periods, at least one 
off-label psychotropic drug prescription and administration was recorded in 96% and 79% of 
the patients, respectively. 
Conclusion: The high rate of off-label psychotropic drug use strengthens the need for clinical 
trials to better evaluate the efficacy and safety of these treatments in adolescents. 
Keywords: Psychotropic drugs; Off-label use; Adolescents; Hospital; Switzerland 
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Introduction 
The prescription of psychotropic drugs among children and adolescents in outpatient settings 
has increased over the past decades, according to studies performed in the United Kingdom 
(Hsia and Maclennan 2009), United States (Olfson et al. 2012), Canada (Meng et al. 2014) 
and Taiwan (Chien et al. 2013). This growing practice is mainly due to the prescription of 
stimulants, atypical antipsychotics and selective serotonin reuptake inhibitors. In addition, high 
cross-national differences in the prevalence of psychotropic drugs prescription have been 
observed. For example, a comparative study performed in 2000 showed a prevalence of 6.7% 
in the United States, 2.9% in the Netherlands and 2.0% in Germany (Zito et al. 2008). 
This high prescription rate raises concerns since a considerable number of these drugs are 
prescribed off-label. A nationwide survey conducted in Australia among general pediatricians 
and child and adolescent psychiatrists in 2000 found that 40% of psychotropic drugs were 
prescribed off-label (Efron et al. 2003). A study performed among all child psychiatrists in the 
Netherlands in 2001 showed that for different psychiatric disorders, off-label prescribing varies 
from 19 to 71% (Hugtenburg et al. 2005). In Germany, a retrospective cohort study revealed 
that 49% of antidepressants were prescribed off-label in 2004-2006 (Dorks et al. 2013). 
The notion of off-label refers to the use of a marketed drug in a situation that does not 
correspond to the terms explicitly recognized by the local authorities, such as Swissmedic in 
Switzerland or the Food and Drug Administration in the United States. In other terms, the 
therapeutic indication, the age, the dosage, the pharmaceutical form and/or the route of 
administration do not correspond to the official authorized use (Neubert et al. 2008). In the 
United States, according to the Committee on Drugs from the American Academy of Pediatrics, 
three-fourths of the prescribed medications lack pediatric use information (American Academy 
of Pediatrics 2002). Only few psychotropic drugs are authorized among this young population 
for treating mental illnesses such as schizophrenia or depression. In addition, despite that 
some atypical antipsychotics are approved to treat a range of conditions such as bipolar 
disorder and childhood schizophrenia, the majority of the pediatric population receiving these 
drugs are getting them for non-approved psychiatric conditions (Pathak et al. 2010).  
To improve the clinical study of drugs in pediatric patients, the FDA Modernization Act (1997), 
followed by the Best Pharmaceuticals for Children Act (2002), incite drug companies to conduct 
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FDA-requested pediatric studies by granting an additional 6 months of marketing exclusivity. 
The Pediatic Research Equity Act (2003) is a complementary program that authorizes the FDA 
to require the study of a new drug in pediatric populations (Bourgeois and Hwang 2017). In the 
European Union, the pharmaceutical companies have to submit a Paediatric Investigation Plan 
since 2007, which aimed at ensuring that the necessary data are obtained through studies in 
children, with the reward of patent extension (European Medicines Agency 2017). 
The active compounds approved for children and adolescent use can vary from one country 
to another according to its regulation policy. Only a few antipsychotics and antidepressants 
have pediatric indications in Switzerland (Table 1). On the contrary, the most common 
benzodiazepines are approved in these patients (Swiss Drug Compendium). 
The problem is more pronounced for hospitalized patients who received a higher number of 
psychotropic medications than in the community. Several studies conducted since 1976 have 
evaluated the prescription of these drugs in children and/or adolescents in psychiatric wards 
in the USA (Zito et al. 1994; Kaplan and Busner 1997; Safer 1997; Pappadopulos et al. 2002; 
Kelly et al. 2004; Lekhwani et al. 2004; Najjar et al. 2004; Pathak et al. 2004; Pogge et al. 
2007; Meagher et al. 2013; Saldana et al. 2014), Canada (Ahsanuddin et al. 1983; Procyshyn 
et al. 2014), Finland (Sourander et al. 2002; Haapasalo-Pesu et al. 2004), France (Winterfeld 
et al. 2008; Consoli et al. 2009), United Kingdom (Akram 2015), Serbia (Pejovic-Milovancevic 
et al. 2011), Israel (Gilat et al. 2011), Australia (Dean et al. 2006) and China (Song and Guo 
2013). The proportion of patients treated with psychotropic medication was high, ranging from 
30% to 100%. Despite the relative important number of studies, the majority have some 
limitations such as the evaluation of a single prevalence period (Ahsanuddin et al. 1983; Zito 
et al. 1994; Kaplan and Busner 1997; Pappadopulos et al. 2002; Sourander et al. 2002; Kelly 
et al. 2004; Lekhwani et al. 2004; Pathak et al. 2004; Dean et al. 2006; Pogge et al. 2007; 
Winterfeld et al. 2008; Consoli et al. 2009; Pejovic-Milovancevic et al. 2011; Procyshyn et al. 
2014; Saldana et al. 2014; Akram 2015), the analysis of prescriptions at a single point during 
hospitalization (Sourander et al. 2002; Haapasalo-Pesu et al. 2004) or at admission and/or 
discharge only (Safer 1997; Lekhwani et al. 2004; Gilat et al. 2011; Meagher et al. 2013; 
Procyshyn et al. 2014; Saldana et al. 2014; Akram 2015), the study of antipsychotics only 
(Pappadopulos et al. 2002; Kelly et al. 2004; Pogge et al. 2007; Procyshyn et al. 2014; Saldana 
et al. 2014), or the inclusion of children only (Lekhwani et al. 2004; Pathak et al. 2004; Akram 
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2015). The rate of off-label prescriptions was evaluated in only three of these studies, at a 
single prevalence period (Winterfeld et al. 2008; Procyshyn et al. 2014; Akram 2015), at 
admission and discharge for antipsychotics (Procyshyn et al. 2014), and at discharge for 
children (Akram 2015). 
To our knowledge, the present study is the first that focused on off-label prescription and 
administration of psychotropic drugs during the entire hospital stay of adolescents in a 
psychiatric ward during two separate periods (2008 and 2014). 
Methods 
Study design and patients 
A retrospective study including data collected in 2008 and 2014 was conducted among 
adolescents (12-18 years old) hospitalized at the Unit of Psychiatric Hospitalization for 
Adolescents (University Service for Child and Adolescent Psychiatry, Department of 
Psychiatry, Lausanne University Hospital, Switzerland). The study was approved by the local 
Ethics Committee.  
Concerning the data collected in 2008, all patients who were admitted between May 1st and 
December 31st, 2008 were included and followed until the end of their hospitalization. The date 
of discharge for the hospitalization of the last patient was April 9th, 2009. Patients admitted 
before May 1st, 2008 but still hospitalized during the study period were not included. In total, 
76 stays were collected over the year 2008. 
For data collected in 2014, the first 76 stays were included in order to have the same number 
as in 2008, to be able to compare results from both periods. The period of admission lasted 
from January 13th to July 21st, 2014. The date of discharge for the hospitalization of the last 
patient was August 25th, 2014. Patients admitted before January 13, 2014 but still hospitalized 
during the study period were not included. 
All data presented in this study are based on the number of stays, that is, if a patient was 
hospitalized twice or more during the study period, each stay was considered independently 
as a new patient. 
Data extraction and analyses 
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For both periods, data was extracted from the electronic prescription and administration 
databases. The demographic data collected included gender, age at admission, psychiatric 
diagnosis at discharge according to the International Statistical Classification of Diseases and 
Related Health Problems (ICD-10), as well as the number and duration of the hospitalizations 
for each patient within the study period. All prescribed and administrated psychotropic drugs 
were collected throughout the entire hospital stay of the patients, including the name of the 
active compound, the pharmaceutical form, the daily doses and the duration of the prescription 
and administration. As some drugs were prescribed as required (pro re nata or prn), a 
distinction was made between prescriptions and administrations. This was possible because 
all administrations actually performed by the nurses were recorded in the electronic database. 
The number of different prescribers was also recorded. 
For every documented psychotropic drug, the pharmaceutical form was taken into 
consideration, therefore separating oral from injectable formulations, as well as oral immediate 
release (IR) from oral extended release (XR) formulations. A total of 5 active compounds were 
separated in this manner: haloperidol (oral versus injectable), levomepromazine (oral versus 
injectable), quetiapine (IR versus XR), lorazepam (oral versus injectable) and biperiden (oral 
versus injectable and IR versus XR).  
The Anatomical Therapeutic Chemical Classification (ATC) was used in order to characterize 
each drug class. All drugs that figured in the N05 (psycholeptic drugs) and N06 
(psychoanaleptic drugs) classes were included in the extractions, including the phytomedicine. 
Drugs from other classes that are usually used in psychiatry were also included, such as 
lamotrigine (N03AX09), valproate (N03AG01), biperiden (N04AA02) and nicotine (N07BA01). 
For each patient and each psychotropic drug, the mean prescribed and administered daily 
dose was calculated. 
The number of different drugs that were either prescribed or administered simultaneously in 
the same patient was also studied. Unlike the rest of the analyses where the pharmaceutical 
forms were separated, the analyses were made according to the active compound. The 
pharmaceutical forms were therefore regrouped. The results were expressed in terms of 
percentage of hospitalization days. 
Off-label use 
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All prescriptions and administrations were analyzed and categorized for off-label use according 
to the approved indications in Switzerland at the moment of the study (2008 and 2014, 
respectively) and the diagnoses of the patients. The reference source employed was the Swiss 
Drug Compendium, approved by Swissmedic, the Swiss Agency for Therapeutic Products 
(Swiss Drug Compendium). Reasons for off-label prescriptions and administrations were 
classified into 6 categories: Age (e.g. citalopram for depression), Diagnosis (e.g. haloperidol 
for anxiety), Age + Diagnosis (e.g. levomepromazine for depression), Pharmaceutical form 
(e.g. haloperidol (injectable) for pervasive developmental disorders), Diagnosis + 
Pharmaceutical form (e.g. quetiapine (XR) for depression) and Dose (ex: lorazepam 17 mg/d 
for anxiety). In order to have a comprehensive approach for the examined parameters, a 
decision-tree was made (Fig. 1). 
Statistical analyses 
Pearson 2 test of independence was used to assess the differences of proportions between 
2008 and 2014; in case the validity of Pearson 2 test was not reliable, the Fisher’s Exact test 
was used instead. Student t-test for independent samples was used to compare continuous 
values between the two study periods; if there were any doubts on the validity of t-tests, the 
Mann-Whitney test was used instead. The number of different psychotropic drugs that were 
prescribed simultaneously in the same patient was assessed with a Poisson regression 
analysis, which is a Generalized Linear Model with logarithmic link function, which is the natural 
link function for count data. A polypharmacy, defined as the simultaneous prescription of 2 
psychotropic drugs or more in the same patient, was assessed with a logistic regression. A p-
value < 0.05 was considered statistically significant. No adjustment for multiple comparisons 
was performed as the prescription of each drug was considered as a different outcome which 
should be studied separately. Statistical analyses were performed using Stata software, 
version 14.0 (StataCorp, College Station, Texas, USA) and R language and environment for 
statistical computing 3.3.1 (R Core Team (2016). R: A language and environment for statistical 
computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.r-
project.org/). 
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Results 
Study population 
A total of 76 stays were analyzed in 2008, corresponding to 64 different patients (55 with 1 
stay, 6 with 2 stays and 3 with 3 stays). In 2014, a total of 76 stays were also analyzed, 
corresponding to 64 different patients (57 with 1 stay, 3 with 2 stays, 3 with 3 stays and 1 with 
4 stays). Based on the total number of stays, the proportion of females was higher in 2008 
(68%) compared to 2014 (49%), p=0.014. The mean age of patients was slightly higher in 2008 
(mean (SD): 16.2 (1.2), range: 12.6-17.9 years) compared to 2014 (mean (SD): 15.5 (1.2), 
range: 12.4-17.6 years), p=0.001, but this difference was not considered clinically significant. 
The duration of hospitalizations was not significantly different between 2008 (median (IQR): 
17.5 (11-28.5), range: 3-115 days) and 2014 (median (IQR): 17 (13-24), range: 2-142 days), 
p=0.90, corresponding to the analysis of a total of 2094 days of hospitalization in 2008 and 
1700 in 2014. There were 7 different prescribers in 2008 and 6 in 2014, with 2 common 
prescribers between the two periods. 
The ICD-10 psychiatric diagnoses were not significantly different between 2008 and 2014 
(Table 2). The main diagnoses were F30-39: Mood [affective] disorders (32.9% of patients in 
2008 and 38.2% in 2014), F40-48: Neurotic, stress related and somatoform disorders (25.0% 
in 2008 and 36.8% in 2014), Z55-65 and Z80-99: Persons with potential health hazards (19.7% 
in 2008 and 26.3% in 2014) and F90-98: Behavioral and emotional disorders with onset usually 
occurring in childhood and adolescence (21.1% in 2008 and 22.4% in 2014). The mean 
number of psychiatric diagnoses reported per patient was slightly lower in 2008 compared to 
2014 (1.8 versus 2.2, p=0.02). The proportion of patients with 1, 2, 3, 4 and 5 diagnoses was 
44.7%, 39.5%, 13.2%, 1.3% and 1.3% in 2008, respectively, and 31.6%, 38.2%, 14.5%, 13.2% 
and 2.6% in 2014, respectively. 
Psychotropic drug prescriptions in 2008 and 2014 
The proportion of patients with at least one psychotropic drug prescription was very high for 
both years: 94.7% in 2008 and 96.1% in 2014, p=1.0 (Fig. 2) and the number of psychotropic 
drugs prescribed increased significantly from 2008 (n=224, mean 2.9 per patient) to 2014 
(n=268, mean 3.5 per patient), p=0.02 for mean values (Table 3). 
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The main prescribed drugs for both years were antipsychotics: n=119 in 2008 (65 typical and 
54 atypical antipsychotics, 53.1% of prescriptions, 73.7% of patients) and n=170 in 2014 (91 
typical and 79 atypical antipsychotics, 63.4% of prescriptions, 85.5% of patients). The 
prescription of antipsychotics increased significantly from 2008 (mean 1.6 per patient) to 2014 
(mean 2.2 per patient), p=0.003. Levomepromazine was the most prescribed antipsychotics 
for both years. The prescription of the injectable form increased significantly between 2008 
(n=15) and 2014 (n=35), p=0.001, and a trend was observed for the prescription of the oral 
form (n=31 in 2008, n=44 in 2014, p=0.051). Quetiapine was the second most prescribed 
antipsychotics. The prescription of the IR form was stable between 2008 (n=15) and 2014 
(n=22), p=0.26, but the prescription of the XR form increased significantly (n=2 in 2008, n=34 
in 2014, p<0.001). The prescription of risperidone was stable between 2008 (n=15) and 2014 
(n=13), p=0.84. A significant decrease in the prescription was observed for olanzapine (16 in 
2008, 5 in 2014, p=0.02) and chlorprothixene (12 in 2008, 1 in 2014, p=0.002). 
The second therapeutic drug class with the highest rate of prescription was anxiolytics for both 
study periods: n=48 in 2008 (21.4% of prescriptions, 53.9% of patients) and n=53 in 2014 
(19.8% of prescriptions, 65.8% of patients). The prescription frequency for anxiolytics was 
stable from 2008 (mean 0.63 per patient) to 2014 (mean 0.7 per patient), p=0.34. Oral 
lorazepam was largely prescribed in both years: n=39 in 2008 and n=48 in 2014, p=0.19. 
The prescription of antidepressants decreased significantly from 2008 (n=23, mean 0.3 per 
patient, 10.3% of prescriptions, 30.3% of patients) to 2014 (n=11, mean 0.14 per patient, 4.1% 
of prescriptions, 13.2% of patients), p=0.01 for mean values. Citalopram was the most 
frequently prescribed antidepressant in 2008 (n=12), but its prescription decrease significantly 
in 2014 (n=1, p=0.002). Inversely, the prescription of sertraline was low in 2008 (n=1), but 
increased significantly in 2014 (n=9, p=0.02). 
The prescription of phytomedicine was stable for both years: n=11 in 2008 (mean 0.14 per 
patient, 4.9% of prescriptions, 11.8% of patients) and n=13 in 2014 (mean 0.17 per patient, 
4.9% of prescriptions, 14.5% of patients), p=0.62 for mean values. 
The prescription of hypnotics had a tendency to decrease from 2008 (n=9, mean 0.12 per 
patient, 4.0% of prescriptions, 7.9% of patients) to 2014 (n=1, mean 0.01 per patient, 0.4% of 
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prescriptions, 1.3% of patients), p=0.052 for mean values. The prescription of zolpidem 
decreased significantly from 2008 (n=6) to 2014 (n=0), p=0.03. 
Up to 5 (mean 1.9) and 6 (mean 2.8) different psychotropic drugs were prescribed 
simultaneously in the same patient in 2008 and 2014, respectively (Fig. 3a). According to 
results of the Poisson regression model, there is a significant increase in the frequency of 
prescribed psychotropics in 2014 compared to 2008 (β=0.40, p=0.01). A polypharmacy, 
defined as the simultaneous prescription of 2 psychotropic drugs or more in the same patient, 
shows a significant increase from 2008 to 2014 with 59.3% and 92.1% of hospitalization days, 
respectively (using a logistic regression model: β=3.1, p<0.0001). 
Psychotropic drug administrations in 2008 and 2014 
The proportion of patients with a least one psychotropic drug administration was 78.9% in 2008 
and 77.6% in 2014, p=1.0 (Fig. 2). A total of 171 psychotropic drugs were administered in 2008 
(mean 2.3 per patient, 76.3% of drug prescribed) and 147 in 2014 (mean 1.9 per patient, 54.9% 
of drug prescribed), p=0.23 for mean values, see supplementary file (Table S1). For both 
years, the number of drugs administered was significantly lower than the number of drug 
prescribed: mean 2.3 and 2.9 per patient in 2008, respectively, (p=0.02) and mean 1.9 and 3.5 
per patient in 2014, respectively, (p<0.0001). 
The main administered drugs for both years were antipsychotics: n=96 in 2008 (43 typical and 
53 atypical antipsychotics, corresponding to 56.1% of administrations and 67.1% of patients) 
and n=98 in 2014 (27 typical and 71 atypical antipsychotics, 66.7% of administrations, 71.1% 
of patients). The administration of antipsychotics was stable for both years (mean 1.3 per 
patient in 2008 and 2014, p=0.71). In 2008, the most administered antipsychotic was 
levomepromazine. The administration of the oral form was stable between 2008 (n=22) and 
2014 (n=21), p=1.0, but the administration of the injectable form decreased significantly (10 in 
2008, 2 in 2014, p=0.03). In 2014, on the other hand, the most administered antipsychotic was 
quetiapine. The administration rate of the IR form was stable between 2008 (n=14) and 2014 
(n=14), p=1.0, but the administration rate of the XR form increased significantly (2 in 2008, 34 
in 2014, p<0.001). The administrations of risperidone were stable between 2008 (n=15) and 
2014 (n=13), p=0.84. The administrations of olanzapine (16 in 2008, 5 in 2014, p=0.02) and 
chlorprothixene (8 in 2008, 0 in 2014, p=0.006) decreased significantly. 
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The second therapeutic class of drugs with the highest rate of administration was anxiolytics 
for both years: n=28 in 2008 (16.4% of administrations, 31.6% of patients) and n=24 (16.3% 
of administrations, 27.6% of patients). The administration of anxiolytics was stable from 2008 
(mean 0.38 per patient) to 2014 (mean 0.32 per patient), p=0.70. In both study periods, oral 
lorazepam was the anxiolytic the most administered: n=22 in 2008 and n=20 in 2014, p=0.86. 
The administration of antidepressants decreased significantly from 2008 (n=22, mean 0.29 per 
patient, 12.9% of administrations, 28.9% of patients) to 2014 (n=10, mean 0.13 per patient, 
6.8% of administrations, 11.8% of patients), p=0.01 for mean values. As for the prescriptions, 
the most frequently administered antidepressant in 2008 was citalopram (n=12), while it was 
sertraline in 2014 (n=8). 
The administration of phytomedicine tended to decrease from 2008 (n=10, mean 0.13 per 
patient, 5.8% of administrations, 11.8% of patients) to 2014 (n=5, mean 0.07 per patient, 3.4% 
of administrations, 3.9% of patients), p=0.08 for mean values. 
The administration of hypnotics tended to decrease from 2008 (n=9, mean 0.12 per patient, 
5.3% of administrations, 7.9% of patients) to 2014 (n=1, mean 0.01 per patient, 0.7% of 
administrations, 1.3% of patients), p=0.052 for mean values. The administration of zolpidem 
decreased significantly from 2008 (n=6) to 2014 (n=0), p=0.03. 
Up to 4 different psychotropic drugs were administered simultaneously in the same patient in 
2008 (mean 1.1) and 2014 (mean 1.0), see Fig. 3b. A Poisson regression model failed to detect 
any significant differences between the two time periods (β=-0.02, p=0.95). A polypharmacy 
was observed in 29.9% and 33.1% of the hospitalization days in 2008 and 2014, respectively, 
which was not significantly different between the two time periods based on a logistic 
regression model (β=-0.46, p=0.36). 
Off-label prescriptions in 2008 and 2014 
A high proportion of off-label prescriptions was observed, with 67.9% of all psychotropic drugs 
in 2008 and 67.5% in 2014, p=0.94 (Table 3). The therapeutic drug classes with the highest 
rate of off-label prescriptions were antidepressants (100% in 2008 and 2014), followed by 
antipsychotics (94.1% in 2008, 91.8% in 2014, p=0.50) and hypnotics (66.7% in 2008, 100% 
in 2014, p=1.0). The proportion of off-label prescriptions was low for anxiolytics (16.7% in 2008, 
11.3% in 2014, p=0.57) and no off-label prescriptions were observed for phytotherapy. 
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A very high proportion of patients (96.1% for both years) were prescribed at least 1 off-label 
psychotropic drug during their hospitalization (Fig. 4). Up to 7 and 6 different off-label 
prescriptions were recorded in the same patient in 2008 and 2014, respectively. 
Off-label administrations in 2008 and 2014 
The rates of off-label administrations were similar to those of the off-label prescriptions, i.e. 
71.3% in 2008 and 71.4% in 2014, p=1.0 (supplementary file Table S1). The highest off-label 
administrations rate was also observed for antidepressants (100% in 2008 and 2014), followed 
by antipsychotics (92.7% in 2008, 90.8% in 2014, p=0.80) and hypnotics (66.7% in 2008, 100% 
in 2014, p=1.0). Off-label administrations were low for anxiolytics (10.7% in 2008, 0% in 2014, 
p=0.24) and were not observed for phytotherapy. 
A high proportion of patients (78.9% for both years) were administered at least 1 off-label 
psychotropic drug during their stay (Fig. 4). Up to 6 different off-label administrations were 
recorded in the same patient in 2008 and 2014. 
Reasons for off-label prescriptions and administrations 
The most frequent category of off-label use in 2008 was “Age + Diagnosis” (64 prescriptions, 
57 administrations) followed by “Age” (59 prescriptions, 47 administrations), see Fig. 1. In 
2014, the most common category of off-label use was “Age” (69 prescriptions, 31 
administrations) followed by “Diagnosis” (34 prescriptions, 29 administrations). 
Discussion 
This retrospective study, which should be considered as exploratory, showed a high 
prevalence of psychotropic drug prescriptions (around 95%) and administrations (around 78%) 
in adolescents in a Swiss psychiatric university hospital over the years 2008 and 2014. 
Globally, the prevalence observed in our study is comparable to those observed in others 
studies performed in children and/or adolescents hospitalized in psychiatry (Ahsanuddin et al. 
1983; Zito et al. 1994; Kaplan and Busner 1997; Safer 1997; Sourander et al. 2002; Haapasalo-
Pesu et al. 2004; Lekhwani et al. 2004; Najjar et al. 2004; Pathak et al. 2004; Dean et al. 2006; 
Winterfeld et al. 2008; Consoli et al. 2009; Pejovic-Milovancevic et al. 2011; Meagher et al. 
2013; Akram 2015). However, large differences have been observed between these studies 
with a prevalence of psychotropic drug use ranging from 30-100%. These differences could be 
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explained by different factors such as the countries, the year of the studies, the type of hospital, 
the profile of the patients or the design of the studies. 
In our study, the number of drugs prescribed simultaneously in the same patient increased 
between 2008 (mean 1.9) and 2014 (mean 2.8). However, the number of drugs administered 
simultaneously was lower and stable between the two study periods (mean 1.1 in 2008 and 
mean 1.0 in 2014), which indicates that many drugs were prescribed as required (prn 
medications) and actually not administered. Our results are in line with those observed in 
different studies conducted in children and adolescents in psychiatry inpatient units of different 
countries, with an average number of psychotropic medications per patient during the stay or 
at discharge varying from 0.8 to 3.1 (Pappadopulos et al. 2002; Dean et al. 2006; Winterfeld 
et al. 2008; Meagher et al. 2013; Song and Guo 2013). 
High percentages of off-label prescriptions (68%) and administrations (71%) were observed in 
the present study, with quite similar results between 2008 and 2014. The rate of off-label 
prescriptions is very close to that found in the study of Winterfeld et al. performed in children 
and adolescents hospitalized in psychiatric units of a teaching hospital in France in 2006, with 
69% of off-label prescriptions (Winterfeld et al. 2008). In both periods of our study, at least one 
off-label psychotropic prescription and administration was recorded in 96% and 79% of the 
patients, respectively. A lower prevalence was observed in the study of Winterfeld et al. where 
only 34% of the patients received one or more off-label psychotropic drugs (Winterfeld et al. 
2008). Another study conducted in a children’s psychiatric unit in United Kingdom from 1997 
to 2012, found that on discharge only 25% of the patients were prescribed an unlicensed 
medicine or a licensed drug used in an unlicensed manner (Akram 2015). 
Antipsychotic use 
The antipsychotics were the most frequently used drugs in this study. The prescription 
increased between 2008 and 2014, mostly due to the higher prescription of levomepromazine 
and quetiapine XR. However, the administrations of antipsychotics were stable between 2008 
and 2014. The administration of quetiapine XR increased between the two study periods, but 
this was compensated by a decrease in the administration of injectable levomepromazine, 
olanzapine and chlorprothixene. Due to its sedative properties, injectable levomepromazine 
was prescribed most of the time as required. Levomepromazine is not approved in Switzerland 
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in patients under the age of 18 years but, in other countries such as France, the oral formulation 
is licensed for the treatment of severe behavioral disorders in pediatric patients (Dictionnaire 
Vidal 2015). The higher prescription rate of quetiapine XR in 2014 compared to 2008 can be 
explained by the fact that this new formulation arrived in the marked in Switzerland at the end 
of 2008. The IR formulation obtained  the pediatric approval from Swissmedic in 2010 (Table 
1), but its prescription rate didn’t increase significantly between 2008 and 2014, indicating the 
preference of the prescribers for the XR formulation. 
By analyzing the prescribing and administration patterns, we found that the majority of typical 
antipsychotics were prescribed as required and were actually not administered (only 44% of 
the prescriptions were administered), whereas this was less the case for atypical 
antipsychotics (93% of the prescriptions were administered). According to the American 
Academy of Child and Adolescent Psychiatry (AACAP) Guidelines, atypical antipsychotics are 
considered as being the treatment of first choice for schizophrenia (except for olanzapine and 
clozapine) (McClellan and Stock 2013). The main atypical antipsychotic drugs used in this 
study were quetiapine, olanzapine and risperidone. These second-generation agents induce 
lower rates of extrapyramidal adverse effects, but cause greater weight gain and metabolic 
risk than the typical antipsychotics (De Hert et al. 2011; Cohen et al. 2012). Furthermore, 
hyperprolactinemia is observed frequently with some atypical antipsychotics, such as 
risperidone. The prescription rate of olanzapine decreased between 2008 and 2014, which 
could be due to the consideration of the highest risk of weight gain with this molecule. 
In addition to quetiapine, the antipsychotics haloperidol, risperidone and aripiprazole have 
pediatric indications in Switzerland (Table 1). It is interesting to point out that even though 
aripiprazole obtained the pediatric approval of Swissmedic for the treatment of schizophrenia 
in 2009 and mania in 2013, the prescription rate seems to be quite stable between 2008 and 
2014. Its approval does therefore not seem to have an impact on the prescription rate. 
It is also important to notice the high proportion of antipsychotics that were prescribed off-label 
(92-94%), which highlights the need to evaluate the aspects of safety, risks and benefits. In 
pediatric patients hospitalized in psychiatry units in France, Winterfeld et al. found that 90% of 
antipsychotic drugs were prescribed off-label (Winterfeld et al. 2008). In children and 
adolescents discharged from a tertiary care inpatient psychiatric facility in 2008-2009 in 
Canada, there were no Health Canada-approved indications for any of the second generation 
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antipsychotics prescribed at the time of the study. Based on the FDA indications, the rate of 
off-label prescribing was 90.5% at discharge (Procyshyn et al. 2014). For the vast majority of 
the patients included in our study, adequate doses were prescribed and administered. 
However, there were some exceptions such as haloperidol with the prescription of up 30 
mg/day and administration of up to 21 mg/day, whereas the recommendation is at 0.5-10 
mg/day for the treatment of mania in adolescents. 
Antidepressant use  
The prescription of antidepressants decreased between 2008 and 2014. A possible 
explanation could be the instauration of the Black-box warning about the use of 
antidepressants and their risk of suicidality in the pediatric population by the FDA in 2004. In 
fact, several papers have noticed a massive drop in the rates of antidepressant prescriptions 
in children and adolescents following the FDA warning (Kurian et al. 2007; Libby et al. 2007; 
Mittal et al. 2014). Even though the Black-box warning was introduced a couple of years before 
our study, the impact of this warning might have been reached several years after. 
A reversal in the prescription pattern of antidepressants can also be seen: the use of citalopram 
decreased from 2008 to 2014, whereas the use of sertraline increased. A potential explanation 
might have been the warnings issued by the FDA in 2011 for the QTc interval prolongation 
with citalopram (US Food and Drug Administration 2012). The change in the prescription 
pattern was considered as adequate, with less risk of cardiotoxicity with sertraline.  
In Switzerland, no antidepressant has been approved for the treatment of depression in 
patients under the age of 18 years. Some of them are indicated in the treatment of obsessive 
compulsive disorder (OCD) in children and adolescents (Table 1). However, in our study, no 
patient had this diagnosis, which explains that we found a rate of off-label prescription of 100% 
for antidepressants. Fluoxetine (≥ 8 years) and escitalopram (≥ 12 years) are indicated in the 
US for treating depression in pediatric patients. Fluoxetine has also obtained the approval by 
the European Medicines Agency (EMA) for treating depression (≥ 8 years) (European 
Medicines Agency 2006). The fact that fluoxetine was prescribed only once in 2008 and not 
prescribed at all in 2014 is quite striking, especially since, according to the National Institute 
for Health and Care Excellence Guidelines (NICE 2005, update 2015) fluoxetine is the first-
choice antidepressant for the treatment of moderate to severe depression among children and 
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adolescents (National Institute for Health and Care Excellence 2015). Furthermore, according 
to a recent network meta-analysis, fluoxetine was the only antidepressant statistically 
significantly more effective than placebo in children and adolescents with major depressive 
disorder (Cipriani et al. 2016). Our results are in accordance with the study of Winterfeld et al., 
which found that 89% of the antidepressants were prescribed off-label (Winterfeld et al. 2008). 
Anxiolytic and hypnotic use 
The anxiolytic drugs come in second place after the antipsychotics in terms of prescription rate, 
with similar number of prescriptions between the two study periods. These drugs were mainly 
prescribed as prn medications, with only 58% and 45% of the prescriptions actually 
administered in 2008 and 2014, respectively. The percentages of off-label prescriptions (11-
17%) are one of the lowest comparing to the rest of the psychotropic drugs. The explanation 
is that the majority of the anxiolytics prescribed are indicated in Switzerland for the treatment 
of anxiety in children and/or adolescent (Table 1). The main reasons for off-label prescription 
were a dose higher than recommended or parenteral administration. In the study of Winterfeld 
et al., 28% of anxiolytics were prescribed off-label (Winterfeld et al. 2008). 
Regarding the use of the hypnotics, a substantial decrease in their prescription rate can be 
seen from 2008 to 2014. This decrease can be perceived as a good evolution since none of 
the hypnotics are currently recommended among the pediatric population (Table 1). 
Strengths and limitations 
A strength of this study is that this is the first that recorded off-label use of psychotropic 
medications during the entire psychiatric hospital stay of adolescents at two separated time 
periods. Another strength is that, in order to have a more realistic and accurate idea of the use 
of off-label psychotropic medications in pediatric patients, both prescriptions and 
administrations were recorded. Indeed, some drugs were prescribed as required, which could 
lead to an overestimation of their use if they were not administered. In addition, some drugs 
prescribed on a regular basis could have not been administered if the patient refused the 
treatment, with is quiet common in psychiatry.  
There are some limitations to this retrospective study, which should be considered as 
descriptive and exploratory. First, the differences of prescriptions between the two study 
periods could have been related to a change of prescribers with different individual habits, 
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rather than a real evolution of the practices in general. Indeed, the number of different 
prescribers was relatively low (7 in 2008 and 6 in 2014), with only 2 common prescribers 
between the two periods. Secondly, it was not possible to know whether all drugs that were 
administered were actually validated by nurses in the electronic database and, inversely, if all 
drugs validated were actually administered; a slight over or under estimation of the real 
administration rates cannot therefore be totally excluded. Thirdly, although some differences 
were statistically significant between the two study periods, the results should be considered 
with caution, as the sample studied was relatively small. Furthermore, it is not possible to know 
if the prescription pattern observed reflects only local practices or if it could be extrapolated to 
other psychiatric hospitals in Switzerland or in Europe. 
Conclusion 
This retrospective study showed a high prevalence of psychotropic drug use in adolescents in 
a psychiatric university hospital in Switzerland. An increase in the number of prescriptions was 
observed between 2008 and 2014, but the number of administrations was stable. 
Antipsychotics were the most frequently prescribed and administered drugs, followed by 
anxiolytics. In addition, a high proportion of these drugs were prescribed and administered off-
label according to the indications approved in Switzerland for both study periods. The 
therapeutic drug classes with the highest rate of off-label prescriptions and administrations 
were antidepressants, followed by antipsychotics. 
Clinical Significance 
A high proportion of off-label psychotropic drug use was observed in this study, despite a lack 
of proven efficacy for most drugs. These results highlight the need for new clinical trials in order 
to evaluate the risks and benefits of psychotropic medications in patients under the age of 18 
years. At the same time, evaluating clinical practice patterns as well as engaging in the 
education of the clinicians concerning the known safety and efficacy of psychotropic drugs is 
an important factor to consider. 
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Table 1. Psychotropic drugs approved in Switzerland in children and adolescents for psychiatric indications a  
Drugs Indications 
Antipsychotics  
Typical antipsychotics  
haloperidol (oral) schizophrenia (≥ 3 years), mania (≥ 3 years), agitation (≥ 3 years) 
promazine acute crisis of chronic psychotic disorder (≥ 12 years) 
Atypical antipsychotics  
aripiprazole (oral) schizophrenia (≥ 13 years) b, manic or mixed episodes in bipolar I disorder (≥ 13 years) c 
quetiapine (IR d) schizophrenia (≥ 13 years) e, manic episodes in bipolar disorder (≥ 10 years) e 
risperidone (oral) behavior disorders in mental retardation (≥ 5 years), hyperactivity and irritability in autistic 
disorders (≥ 5 years), manic episodes in bipolar disorder (≥ 15 years)  
Antidepressants  
Tricyclic antidepressants  
clomipramine obsessive compulsive disorder (≥ 10 years) 
Selective serotonin reuptake inhibitors 
fluvoxamine obsessive compulsive disorder (≥ 8 years) 
sertraline obsessive compulsive disorder (≥ 6 years) 
Anxiolytics/hypnotics  
Benzodiazepines and analogs  
bromazepam anxiety (≥ children) 
clobazam anxiety (≥ 3 years) 
clorazepate (oral) anxiety (≥ 9 years) 
diazepam (oral + injection) anxiety (≥ children) 
lorazepam (oral) anxiety (≥ 12 years) 
oxazepam anxiety (≥ 12 years) 
prazepam anxiety (≥ 3 years) 
zolpidem - f 
Antihistaminics  
diphenhydramine sleep disorders (≥ 2 years) 
doxylamine sleep disorders (≥ 12 years) 
hydroxyzine - g  
Attention deficit hyperactivity disorder (ADHD) 
atomoxetine ADHD (≥ 6 years) 
dexmethylphenidate ADHD (≥ 6 years) 
lisdexamphetamine ADHD in case of inadequate response to methylphenidate (≥ 6 years) 
methylphenidate ADHD (≥ 6 years) 
Others  
biperiden (IR d, injection) extrapyramidal disorders (≥ 0 year for injection; ≥ 3 years for IR) 
lithium acute phase and long term prophylaxis of bipolar disorder (≥ 12 years), co-medication 
with antidepressants for resistant depression (≥ 12 years) 
nicotine - h 
a according to www.compendium.ch (last update August 2017); b since 2009; c since 2013; d IR: oral form with 
immediate release; e since 2010; f initially contraindicated in adolescents < 15 years, suggesting a possible use in 
adolescents ≥ 15 years, but the label has changed in 2009 stating that zolpidem should not be used in patients < 18 
years; g initially approved for anxiety in children and adolescent ≥ 1 year, but this indication was withdrawn in 2016; h 
approved in adults for smoking cessation, but could be used in adolescents ≥ 12 years with strong dependence to 
nicotine. 
 
  
Table 2. ICD-10 psychiatric diagnoses of the patients 
Diagnoses a 
Number (%) of patients b  
Year 2008 
n=76 
Year 2014 
n=76 
P-value * 
F10-19: Mental and behavioural disorders due to psychoactive 
substance use 
8 (10.5) 5 (6.6) 0.56 
F20-29: Schizophrenia, schizotypal and delusional disorders 7 (9.2) 7 (9.2) 1.00 
F30-39: Mood [affective] disorders 25 (32.9) 29 (38.2) 0.61 
F40-48: Neurotic, stress-related and somatoform disorders 19 (25.0) 28 (36.8) 0.16 
F50-59: Behavioral syndromes associated with physiological 
disturbances and physical factors 
11 (14.5) 4 (5.3) 0.10 
F60-69: Disorders of adult personality and behavior 3 (3.9) 5 (6.6) 0.72 
F70-79: Mental retardation 1 (1.3) 1 (1.3) 1.00 
F80-89: Disorders of psychological development 4 (5.3) 10 (13.2) 0.16 
F90-98: Behavioral and emotional disorders with onset usually 
occurring in childhood and adolescence 
16 (21.1) 17 (22.4) 1.00 
X60-X84: Intentional self-harm 11 (14.5) 17 (22.4) 0.30 
Z55-65 and Z80-99: Persons with potential health hazards 15 (19.7) 20 (26.3) 0.44 
Q86: Congenital malformation syndromes due to known 
exogenous causes, not elsewhere classified 
0 (0.0) 3 (3.9) 0.25 
a diagnoses at discharge ; b one or more diagnoses per patient ; * Fisher’s exact test 
 
 
Table 3. Prescriptions of psychotropic drugs in hospitalized adolescents in 2008 (n=76 patients) and 2014 (n=76 patients) 
Drugs 
Prescriptions,  
n (mean/patient) 
Off-label prescriptions, n (%) a Dose [mg/day], median (range) b 
Duration of prescription [day],  
median (range) 
 2008 2014 2008 2014 2008 2014 2008 2014 
Antipsychotics         
Levomepromazine (oral) 31 44 31 (100%) 44 (100%) 50 (15-108) 60 (15-164) 16 (3-111) 15 (4-56) 
Levomepromazine (inj)   15 *   35 * 15 (100%) 35 (100%) 50 (13-78) 50 (20-109) 8 (3-28) 15 (3-84) 
Quetiapine (IR) c 15 22   15 (100%) *   13 (59.1%) *   274 (25-485) #   82.5 (25-400) # 17 (1-108) 13 (1-86) 
Quetiapine (XR) d   2 *   34 * 2 (100%) 34 (100%) 131 (50-213) 254 (50-800) 32 (1-63) 14 (2-58) 
Olanzapine   16 *   5 * 16 (100%)  5 (100%)  11 (3-20) #  20 (12-20) # 16 (2-50) 15 (9-82) 
Risperidone 15 13 8 (53.3%) 10 (76.9%) 2 (0.5-4) 1 (0.5-3.4) 8 (3-28) 14 (2-138) 
Chlorprothixene   12 *   1 * 12 (100%) 1 (100%) 30 (15-75) 30 (30-30) 11 (2-38) 4 (4-4) 
Haloperidol (oral) 1 5 1 (100%)  4 (80%) 30 (30-30) 2.7 (2-21) 15 (15-15) 7 (2-74) 
Haloperidol (inj) 6 6 6 (100%) 6 (100%) 5 (5-10) 7.5 (5-15) 14 (2-22) 8.5 (4-84) 
Amisulpride 4 3 4 (100%) 3 (100%) 600 (600-644) 200 (190-719) 20 (3-64) 14 (4-36) 
Aripiprazole 1 2 1 (100%)  1 (50%) 10 (10-10) 6.8 (5.7-7.8) 12 (12-12) 12 (7-16) 
Clozapine 1 0 1 (100%) - 218 (218-218) - 10 (10-10) - 
Subtotal   119 (1.6) #   170 (2.2) # 112 (94.1%) 156 (91.8%)     
Antidepressants         
Citalopram   12 *   1 * 12 (100%) 1 (100%) 20 (10-60) 20 (20-20) 15 (4-100) 30 (30-30) 
Escitalopram 4 0 4 (100%) - 10 (10-15) - 49 (3-92) - 
Mirtazapine 4 0 4 (100%) - 27 (20-30) - 35 (9-107) - 
Sertraline   1 *   9 * 1 (100%) 9 (100%) 50 (50 -50) 50 (46-100) 11 (11-11) 16 (2-89) 
Fluoxetine 1 0 1 (100%) - 40 (40-40) - 7 (7-7) - 
Clomipramine 1 0 1 (100%) - 25 (25-25) - 15 (15-15) - 
Duloxetine 0 1 - 1 (100%) - 30 (30-30) - 96 (96-96) 
Subtotal   23 (0.30) #   11 (0.14) # 23 (100.0%) 11 (100.0%)     
Hypnotics         
Zolpidem   6 *   0 * 3 (50%) - 9 (5-12.5) - 9.5 (2-33) - 
Zopiclone 3 1 3 (100%) 1 (100%) 7.5 (4-7.5) 7.5 (7.5-7.5) 12 (2-26) 11 (11-11) 
Subtotal 9 (0.12) 1 (0.01) 6 (66.7%) 1 (100.0%)     
        (continued) 
 
  
Table 3. (continued) 
Drugs 
Prescriptions,  
n (mean/patient) 
Off-label prescriptions, n (%) a Dose [mg/day], median (range) b 
Duration of prescription [day],  
median (range) 
 2008 2014 2008 2014 2008 2014 2008 2014 
Anxiolytics         
Lorazepam (oral) 39 48 3 (7.7%) 5 (10.4%) 3 (1-17) 3 (1-11) 12 (1-64) 16 (1-96) 
Lorazepam (inj) 4 1 4 (100%) 1 (100%) 5.5 (2-12) 8 (8-8) 10 (7-17) 3 (3-3) 
Oxazepam 2 0 0 (0%) - 38 (31-45) - 18 (3-32) - 
Alprazolam 1 0 1 (100%) - 1.5 (1.5-1.5) - 4 (4-4) - 
Bromazepam 1 0 0 (0%) - 3 (3-3) - 3 (3-3) - 
Clorazepate 1 1 0 (0%) 0 (0%) 5 (5-5) 10 (10-10) 7 (7-7) 14 (14-14) 
Diazepam 0 1 - 0 (0%) - 10 (10-10) - 5 (5-5) 
Hydroxyzine 0 2 - 0 (0%) - 74 (48-100) - 13 (12-14) 
Subtotal 48 (0.63) 53 (0.70) 8 (16.7%) 6 (11.3%)     
Phytotherapy         
Phytotherapy “Sleep” e 9 6 0 (0%) 0 (0%) 1 (1-1) h 1 (1-1) h 27 (6-84) 18 (5-63) 
Phytotherapy “Sleep Strong” f 1 5 0 (0%) 0 (0%) 1 (1-1) h 1 (1-1) h 67 (67-67) 19 (3-22) 
Phytotherapy “Relaxing” g 1 2 0 (0%) 0 (0%) 1 (1-1) h 1.6 (1.2-2) h 25 (25-25) 37 (10-63) 
Subtotal 11 (0.14) 13 (0.17) 0 (0.0%) 0 (0.0%)     
Others         
Nicotine   6 *   0 * 0 (0%) - 8 (6-16) - 14 (5-19) - 
Biperiden (IR) c 3 8 0 (0%) 0 (0%)  3.5 (2-5) #  2 (1-2) # 22 (2-22) 15 (3-84) 
Biperiden (XR) d 1 4 1 (100%) 4 (100%) 4 (4-4) 3 (2-4) 14 (14-14) 19 (11-82) 
Biperiden (inj) 2 5 0 (0%) 1 (20%) 4 (3-5) 5 (2.5-7.5) 8.5 (3-14) 4 (3-84) 
Valproate 1 0 1 (100%) - 600 (600-600) - 20 (20-20) - 
Methylphenidate 1 0 1 (100%) - 36 (36-36) - 4 (4-4) - 
Atomoxetine 0 1 - 0 (0%) - 25 (25-25) - 15 (15-15) 
Lamotrigine 0 1 - 1 (100%) - 12.5 (12.5-12.5) - 6 (6-6) 
Melatonin 0 1 - 1 (100%) - 3 (3-3) - 8 (8-8) 
Subtotal 14 (0.18) 20 (0.26) 3 (21.4%) 7 (35.0%)     
TOTAL   224 (2.9) #   268 (3.5) # 152 (67.9%) 181 (67.5%)     
a according to the approved indications in Switzerland at the moment of the study (2008 and 2014); b for each patient, a mean daily dose prescribed during the study period was calculated, the median (range) of these 
mean doses are reported here; c immediate drug release; d extended drug release; e Valerian Root dry extract 250 mg and Hop Strobile dry extract 60 mg; f Valerian Root dry extract 500 mg and Hop Strobile dry extract 
120 mg; g Butterbur Root dry extract 90 mg, Passion Flower dry extract 90 mg, Valerian Root dry extract 90 mg and Melissa Leaf dry extract 60 mg; h dose expressed as tablet; * Fisher’s exact p-value < 0.05 between 
2008 and 2014; # Mann-Whitney p-value < 0.05 between 2008 and 2014. 
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Figure legends 
Fig. 1 Decision-tree classifying the reasons of off-label prescriptions and administrations. 
Pharm. form: Pharmaceutical form; P-08/14: number of prescriptions in 2008 and 2014, 
respectively; A-08/14: number of administrations in 2008 and 2014, respectively; *Fisher’s 
exact p-value < 0.05 between 2008 and 2014. 
Fig. 2 Percentage of patients with at least one prescription or administration of the different 
therapeutic classes of drugs. *Fisher’s exact p-value between 2008 and 2014. 
Fig. 3 Number of different psychotropic drugs prescribed (a) and administered (b) 
simultaneously per day in the same patient in 2008 and 2014. In 2014, 6 different 
psychotropic drugs were prescribed 0.1 % of the days (data not shown in the figure). 
*Poisson regression p-value between 2008 and 2014. 
Fig. 4 Percentage of patients with off-label psychotropic prescriptions or administrations. 
*Fisher’s exact p-value between 2008 and 2014. 
